

## **EPTS OpenMRS**

# Reports Requirements Indicator Specification Document TX\_CURR

**Draft Version 2.6** 





# Version

Date	Versi on	Description	Author(s)
July 24, 2018	1.0	Initial creation of document	Maria Rein
July 30, 2018	1.1	Incorporated edits from Joel	Maria Rein
August 10, 2018	1.2	Incorporated edits from Joel	Maria Rein
September 30, 2018	2.0	Document structure updated	Pinki Meggi
October 19, 2018	2.1	Updated according to MER Indicator reference guide version 2.3	Kétmia Matavele
October 26, 2018	2.2	Structure and content updated: "Business Process" and diagrams added, requirements list updated, technical requirements added, annexes added.	Kétmia Matavele
November 6, 2018	2.3	Structure and Content updated: additional FGH and Jembi Logos added, chapter III renamed from "Business Process" to "Report Process Analysis", legend added for report process diagrams, requirements list updated, bookmarks added for requirements, pseudo code added in technical requirements and approval section added after versioning section.	
November 11, 2018	2.4	Overall Revision	Zainabe Dadá
November 28, 2018	2.5	Overall revision on key assumptions and depth FGH To technical review	
December 7, 2018	2.6	FGH changes and overall revision: business process, key assumptions, requirements, pseudocode, technical requirements and annexes udpated.	

# **Approvals and Sign-off**

#### **Approvals Panel**

Version	Approver	Approved by	Date
2.6	CDC		

#### **Approvals Panel**

The Approver signatures signify that this document has been reviewed and satisfies the project governance, business and system needs.

**Document Title:** EPTS OpenMRS Indicator Specification and Requirements – TX\_CURR **Year:** 2018

#### **Authors Signature**

Version	Authors	Approved by	Date
2.6	FGH		
	Jembi Health Systems	Pinki Meggi	

#### Authors

The Authors signatures represent the EPTS Requirements Gathering Group composed by two CDC Partners, Jembi Health Systems (HIS Partner) and FGH (Clinical Partner) and signify that this document is complete and that, to the best of their knowledge, it adequately addresses the document's intended purpose and scope and it is accurate.

# **Table of Contents**

Version	1
Table of Contents	2
I Introduction I.a Purpose I.b Scope and Key Assumptions I.c References	4 4 4 4
<ul> <li>II. Indicator Definition <ul> <li>II.a Description</li> <li>II.b Numerator and Denominator</li> <li>II.c Indicator Reporting Level and Frequency</li> <li>II.d Indicator Primary Sources</li> <li>II.e Population</li> <li>II.f Disaggregation</li> <li>II.g Report Output</li> </ul> </li> </ul>	5 5 5 5 6 6 6
III. Business Process definition	6
IV. Requirements Definition IV.a Key Assumptions IV.b List of Functional Requirements	9 9 9
V. Testing Scenarios	11
VI. Technical Specifications	11
VII. ANNEXES	16

# I Introduction

### I.a Purpose

The purpose of this document is to capture the requirements and specifications for the PEPFAR MER **TX\_CURR** Indicator. This indicator is reported from the EPTS OpenMRS system in use by the PEPFAR Clinical partners to capture patient level data in retrospective mode at the health facilities.

#### I.b Scope and Key Assumptions

This document explains the indicator definition, describes the indicator reporting process, and defines the functional and technical requirements to generate the indicator in an OpenMRS Report. The link to testing scenarios document is also included.

The indicator definition is based on PEPFAR MER (Monitoring, Evaluation, and Reporting) Indicator Reference Guide specified below in I.c References.

The key Assumptions are:

All patients captured in the OpenMRS system are HIV positive.

All patients captured in the OpenMRS system have been on antiretroviral therapy (ART) at some time.

All transferred in patients are HIV positive and are on ART.

### **I.c References**

MER 2.3 Indicator Reference Guide

## **II. Indicator Definition**

## II.a Description

TX\_CURR indicator reports the number of adults and children currently receiving antiretroviral therapy (ART) which is also the indicator Numerator.

This indicator measures the ongoing scale-up and uptake of ART and retention in ART programs as a critical step in the HIV service cascade and assesses progress towards coverage of ART for all eligible HIV-positive individuals.

The guiding questions are:

1. What percentage of clients is picking up their ART drugs on a quarterly basis? On a semi-annual basis? 2. What percentage of clients is being seen for clinical followup visits on a quarterly basis? On a semi-annual basis? On an annual basis?

#### **II.b Numerator and Denominator**

TX\_CURR **numerator** is the number of adults and children currently receiving antiretroviral therapy (ART).

TX\_CURR **denominator** is not applicable for this indicator.

### **II.c Indicator Reporting Level and Frequency**

TX\_CURR is a **Facility-level** indicator, collected at this same level and reported at fixed geographic points (sites) providing HIV related services.

TX\_CURR is reported at each **quarterly** reporting cycle.

The PEPFAR partners are required to report quarterly for the following reporting periods:

Q1 September 21<sup>st</sup> - December 20<sup>th</sup>

- Q2 December 21<sup>st</sup> March 20<sup>th</sup>
- Q3 March 21<sup>st</sup> June 20<sup>th</sup>
- Q4 June 21<sup>st</sup> September 20<sup>th</sup>

TX\_CURR Indicator is reported in Q1, Q2, Q3 and Q4 for correspondent 3 months of results.

#### **II.d Indicator Primary Sources**

The TX\_CURR indicator should be collected from:

- Facility ART registers (Livro TARV) / databases (OpenMRS)
- Program monitoring tools (Ficha de Seguimento e Fila)
- Drug supply management systems (Pharmacy Systems)

## **II.e Population**

TX\_CURR population **includes**:

- Patients on ART who initiated or transferred-in during the reporting period.
- Patients that pick up several months of antiretroviral drugs at one visit that last to the end of reporting period;
- HIV-positive pregnant women who
  - O have newly initiated ART during the current pregnancy or
  - $\bigcirc$  are already on ART at the beginning of the current pregnancy

TX\_CURR population **excludes**:

- Patients who died;
- Patients who stopped the treatment;
- Patients who are transferred out;
- Patients who are lost to follow-up (if the patient is being traced it's not lost to follow-up).
- Patients who have not received ARVs within four weeks of their last missed drug pick-up.

## **II.f Disaggregation**

The TX\_CURR Indicator should be reported disaggregated by Sex and Age. The Sex disaggregation is female and male. The Age disaggregation is <1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50+ and Unknown Age.

CURRENT is a state defined by treatment status when last seen, so it is expected that characteristics of these patients would be updated each time they are seen by a program.

Age represents an individual's age at the end of the reporting period or when last seen at the facility. For example, a 14-year-old child will be counted as currently receiving treatment in the <15 age category at the end of reporting period "A". During reporting period "B" the child turns age 15 and so at the end of this reporting period the child will be counted under the 15+ age category.

## II.g Report Output

The report output for TX\_CURR indicator can be found <u>here</u>.

## **III. Report Process Analysis**

The main report process to generate the TX\_CURR indicator report based on Indicator Definition and Business Requirements (II. Indicator Definition) is the following:

#### **BP1. PEPFAR MER Quarterly Report Generation Process**



Figure 1 BP1 - Report Process for PEPFAR MER Quarterly Report Generation

Legend:

	Green Start point	The green circle shows where the process starts.
Red End point		The red circle shows where the process ends.
	Direction Arrow	The arrows show you the direction of the process flow.
Sequence #. Description	Blue tasks	The blue tasks represent the simple tasks that are part of the process.
Sequence #. Description	Yellow Tasks	The yellow tasks represent group of tasks or a sub-process which is detailed in another process diagram.
Main Task description	Grouper with multiple tasks	Some tasks are grouped together. This represents multiple tasks that could be performed in differed sequences but are part of the main task specified in the top.

#### **BP2. TX\_CURR Indicator Report Generation Process**



Figure 2 Report Process for TX\_CURR Report Generation (BP2)



#### **BP3. TX\_CURR Indicator Numerator Selection Process**

Figure 3 Report Process for TX\_CURR Indicator Numerator Identification (BP3)



**BP4. TX\_CURR Numerator Disaggregation Process** 

# **IV. Requirements Definition**

## IV.a Key Assumptions

The key assumptions for TX\_CURR indicator and related to EPTS OpenMRS are the following:

- 1. All patients captured in the OpenMRS system are HIV positive.
- 2. All patients captured in the OpenMRS system have initiated antiretroviral therapy (ART) at some time.
- 3. All transferred-in patients are HIV positive and are on ART.
- 4. All patients captured in the OpenMRS- this doesn't include the PEP (Post exposure prophylaxis) patients.
- 5. The primary source for TX\_CURR are "FILA" (<u>Annex 1</u>), "Ficha de Seguimento do Adulto" (<u>Annex 2</u>), "Ficha de Seguimento de Pediatria" (<u>Annex 3</u>).
- 6. The patients in ART program are enrolled in SERVIÇO TARV-TRATAMENTO;
- All patients must be officially enrolled on ART Service at end of reporting period on specified health facility. Officially enrolment mean 1) have "Processo Clinico Parte A" registered in health facility or 2) has been enrolled in "SERVICO TARV - CUIDADO" program in health facility or 3) has been enrolled in "SERVICO TARV - TRATAMENTO" as "Transferred in" in health facility.
- 8. The PEPFAR MER Reports in OpenMRS are named "PEPFAR MER 2.3 Quarterly" report for quarterly reporting (Q1, Q2, Q3, Q4), "PEPFAR MER 2.3 Semi-Annual" report for semi-annual reporting (S1, S2), and "PEPFAR MER 2.3 Annual", report for annual (APR) reporting.

Requirem ent #	Category/ Functional Area	Requirement
CURR_FR1	Reports	The system will generate the TX_CURR indicator report (CURR_FR2) under "PEPFAR MER Quarterly Report" for selected reporting period (start and end date) and specific location (health facility).
CURR_FR2	Indicator numerator	<ul> <li>The system will generate TX_CURR indicator <b>numerator</b> as number of patients (adult and children) on ART by end of reporting period (CURR_FR8) with the specified disaggregation (CURR_FR3).</li> <li>This <b>includes</b> the following patients <ul> <li>Patients who ever started ART by end of reporting period (CURR_FR4);</li> <li>Patients who were transferred-in from another health facility</li> </ul> </li> </ul>

#### **IV.b List of Functional Requirements**

CURR_FR3	Indicator Disaggregati on- numerator	<ul> <li>by end of reporting period (<u>CURR_FR41</u>).</li> <li>The system will <b>exclude</b> the following patients: <ul> <li>Patients who left the ART Program (<u>CURR_FR5</u>) for following reasons: died or stopped the treatment or were transferred out to another health facility.</li> <li>All patients who are Lost to follow up and who did not receive ARVs within four weeks of their last missed drug pick-up (<u>CURR_FR6</u>).</li> </ul> </li> <li>The system will generate the TX_CURR indicator <b>numerator</b> with following disaggregation: <ul> <li>Children</li> <li>Sex: Male/Female</li> <li>Age: &lt;1, 1-4, 5-9 (<u>CURR_FR7</u>)</li> </ul> </li> <li>Adults <ul> <li>Sex: Male/Female</li> <li>Age: 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, &gt;=50, Unknown age (<u>CURR_FR7</u>)</li> </ul> </li> </ul>	
CURR_FR4	Patients who ever initiated treatment	The system will identify patients who ever <b>initiated treatment</b> as	
CURR_FR4 1	Patients who were transferred- in	<ul> <li>The system will identify patients who were transferred in from other facility as following:</li> <li>All patients enrolled in ART Program by end of reporting period and has been registered in follow up clinical visits ad TRANSFERRED IN FROM OTHER FACILITY</li> </ul>	
CURR_FR5	Patients who are Lost to follow-up	<ul> <li>The system will identify Lost to follow-up patients as following:</li> <li>All patients who missed the pickup drugs (Fila) 4 weeks after the following scheduled drug pickup</li> <li>All patients who missed the follow up consultation (<i>Ficha de Seguimento Adulto and Ficha de Seguimento Pediatria</i>) 4 weeks after the following scheduled return visit date</li> <li>Patients who doesn't have the next drug pick up date and next consultation date scheduled</li> </ul>	
CURR_FR6	Patients who left ART Program	The system will identify patients who are enrolled on ART Program (Service TARV- Tratamento) but <b>who left the ART Program</b> for the following reasons that are specified in the patient chart as state of patient: O Died O Transferred out to another health facility	

		<ul> <li>Stopped/suspended the treatment</li> <li>Abandoned the treatment</li> </ul>	
CURR_FR7	Patients Disaggregati on- age	<ul> <li>The system will identify patients age for disaggregation intervals as following:</li> <li>Patients with birth date information registered in the system should be calculated the age of the patient at the reporting end date (birth date minus reporting end date)</li> <li>Patients without birth date information should be considered as unknown age.</li> </ul>	
CURR_FR8	Reporting Period	The user will enter as input parameters the "reporting start date" and "reporting end date". The <b>"reporting start date"</b> is defined by the beginning of the correspondent quarter reporting period. The <b>"reporting end date"</b> is defined by the end of the reporting period. Q1 September 21st - December 20th Q2 December 21st - March 20th Q3 March 21st - June 20th Q4 June 21st - September 20 <sup>th</sup>	

# **V. Testing Scenarios**

<to be included here>

# **VI. Technical Specifications**

### VI.a Pseudo-code

Input: startDate and endDate (from selected quarter):

#### Pseudo-code:

For each Health Facility:

1. Get all patients (adults, pediatrics, pregnant) who

- Ever started ART at end of reporting period (<u>CURR\_FR4</u>)
- AS Patient\_List (including patientID, birthdate, sex)
  - 1.1Exclude from Patient\_List:
    - 1.1.1 Patients who left ART Program ( CURR\_FR6)
    - 1.1.2 Lost to follow up patients (CURR\_FR5)
- 2. if exist patients in Patient\_LIST

[

- 2.1Identify and count children (age <1-9) subtracting the endDate and patient birthdate:
  - 2.1.1 Disaggregate and count patients by sex (male and female);
  - 2.1.2 For each sex male and female group, disaggregate and count per age group (<1, 1-4, 5-9) subtracting the endDate and birthdate;
  - 2.1.3 Calculate the subtotals.

2.2 Identify and count adults (age >9) subtracting the endDate and birthdate:

2.2.1 Disaggregate and count patients by sex (male and female);

2.2.2 For each sex male and female group, disaggregate and count per age group (10-14, 15-19, 20-24,25-29,30-34,35-39,40-44,45-49, >=50, Unknown age) subtracting the endDate and birthdate;

2.2.3 Calculate the subtotals.

2.3 Report the numerator values

]

Else report "0" for numerator for all disaggregation END Simplified OPTION PSEUDOCODE

### VI.b Data fields and elements

- Define the data element(s) used to determine the reporting range
   The reporting range dates will be specified by user before submitting the report request as "startDate", "endDate".
- Define the data element(s) used to determine if a patient has ever enrolled in ART

Encounter Type/ Table	Data Element(s)	Data Element Value
--------------------------	-----------------	--------------------

Patients on ART who initiated the ARV DRUGS Patients	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9) ) S.TARV: FARMACIA (ID=18) Patient PROGRAM	ARV PLAN (OBS CONCEPT ID = 1255) MINUMUM Encounter DATE (encounter. encounter_datetime) (patient_program.	START DRUGS ( OBS Value Code =1256 ) <= endDate SERVICO TARV -
transferred in from other facility		Program_id) Program Enrolment Date (patient_program. Date_enrolled)	TRATAMENTO ( program_id =2 ) <= endDate
	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9) ) S.TARV: FARMACIA (ID=18)	ARV PLAN (OBS CONCEPT ID = 1255) MINUMUM Encounter DATE (encounter. encounter_datetime)	TRANSFERRED FROM OTHER HF ( OBS Value Code = 29 ) <= endDate
Patients on ART who have historical date of ART start	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9) ) S.TARV: FARMACIA (ID=18)	MINIMUM HISTORICAL START DATE ( OBS CONCEPT ID 1190)	<= endDate
Patients enrolled in ART Program		Patient PROGRAM (patient_program. program_id) Program Enrolment Date (patient_program. Date_enrolled)	SERVICO TARV - TRATAMENTO ( program_id =2 ) <= endDate
Patients with first drugs pick up date set in Pharmacy	S.TARV: FARMACIA (ID=18)	MINIMUM Encounter DATE (encounter. encounter_datetime)	<= endDate

#### • Define the data element(s) used to determine lost to follow up patients

	Encounter Type	Data Element(s)	Data Element Value
Patients who doesn't have the next drug pick up date and next	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA	Encounter DATE (encounter. encounter_datetime)	Last_scheduled_visit = max (encounter_datetime) for encounter(6,9)
consultation date scheduled	SEGUIMENTO(ID= 9) S.TARV: FARMACIA (ID=18)	Last scheduled visit (OBS CONCEPT ID = 1410)	Last_art_pick_up = max (encounter_datetime) for encounter (18)
		Last scheduled ART PICK UP DATE (OBS CONCEPT ID =	

		5096)	
Patients who missed the drugs pick up visit	S.TARV: FARMACIA (ID=18)	Encounter DATE max (encounter. encounter_datetime) Last scheduled ART PICK UP DATE (OBS CONCEPT ID = 5096)	Max (encounter_datetime) <= endDate and last_art_pick_up > max(encounter_datetime) and (Last_art_pick_up + 4 weeks < endDate)
Patients who missed the consultation	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID= 9)	Encounter DATE max (encounter. encounter_datetime) Last scheduled visit (OBS CONCEPT ID = 1410)	Max (encounter_datetime) <= endDate and last_scheduled_visit > max(encounter_datetime) and (Last_scheduled_visit + 4 weeks < endDate)

- Define the data elements used to identify the gender of the patient: patient.sex
- Define the data elements used to identify the patient's age: *patient.birthdate*
- Define the data elements used to identify if a patient is dead:
  - Patient\_program.program\_id =2 = SERVICO TARV-TRATAMENTO
  - o Patient\_State.state = 10 = DIED
  - o Patient\_State.start\_date <= endDate</pre>
  - o Patient\_state.end\_date is null
- Define the data elements used to identify if a patient has transferred out
  - **0** *Patient\_program.program\_id =2 = SERVICO TARV-TRATAMENTO*
  - *Patient\_State.state = 7 = Transferred out to another health facility*
  - o Patient\_State.start\_date <= endDate
  - o Patient\_state.end\_date is null
- Define the data elements used to identify if a patient has been marked as "lost to follow up"
  - Patient\_program.program\_id =2 = SERVICO TARV-TRATAMENTO
  - o Patient\_State.state = 9 = Abandoned the treatment
  - o Patient\_State.start\_date <= endDate</pre>
  - o Patient\_state.end\_date is null
- Define the data elements used to identify if a patient has stopped the treatment
  - **0** *Patient\_program\_program\_id =2 = SERVICO TARV-TRATAMENTO*
  - o *Patient\_State.state = 8 = Stopped/suspended the treatment*
  - o Patient\_State.start\_date <= endDate</pre>

o Patient\_state.end\_date is null

# **VII. ANNEXES**

## Annex 1- OpenMRS EPTS FILA

OpenMRS				Entrou no sistema como Bombe	er Budaa Spain   <u>Sair do Sistema</u>   <u>Meu Perfil</u>   <u>Ajuda</u>		
	Página Inicial   Procurar/Reg	istar Pac	iente   Dicionário	Cohort Builder   Reporting   Adminis	traçăo		
Discard changes   Print		Maria C	arlos   FILA (S.TARV: F	ARMACIA)   (Unsaved Form)			
			Ficha Individual de Levantamento de ARVs (FILA)				
	REPÚBLICA DE MOÇAMBIQUE Serviço Nacional de Saúde	Nº do Livr	o TARV: Pag: Linha:				
				Maria Carlos			
	NID: 01080805/17/00010		Contacto: Endereço:				
	ND: 01080803/17/00010		Endereço:				
	Data de Leva	ntamento:					
		Provedor:	Enter				
	Unidade	Sanitária:	Local Desconhecido	•			
	Medicamer	ntos ARVs:	Ultimo Regime:	•			
	Quantida	de Aviada:	- Outra:				
		Dosagem:	- Outra:				
	Data do próximo Leva	ntamento:	*				
			Submeter				

#### Annex 2- OpenMRS EPTS Adulto Seguimento

Página Inicia	I   Procurar/Registar Pacien	e   Dicio	nário   Cohort Builde	Entreu no sistema como Bomb er   Reporting   Admin		
int	Maria Carlos   ADULTO: SEGUIMENTO (S.TARV: ADULTO SEGUIMENTO)   (Unsaved For					
FICHA DE SEGUIMENTO PARA ADULTOS						
REPÚBL	ICA DE MOÇAMBIQUE NACIONAL DE SAUDE	Nome:Maria C				
		Data de nasci	mento: 17/out/2018	Idade: 0- Sexo: F		
	Nº do livro pré-TARVI	Página do live		Linha da Páp do pré-TAR		
NED: 01080805/17/000	Nº do livro TARU:	Página do livr		Linha da Pág do TARV:		
	Dete de Consulta		1			
	Unidade Sanitária	Local Desco	nhecido •			
Alturat	Médico cm)(Útima Altura: ]	Enfant				
	Peso(kg)					
1/	ndice de Hassa Corporal (BHC):(kg/m2)					
	Classificação Nutricional: Apoio Nutricional (ANUT)		•	Rear Barlow and A. C. Star		
	Temperatura (°C):	S S S N TH	No: CSB Plumpy Nut C	Papa Enriquecida 🗆 Outro		
	Tensão Arterial (TA)	U.				
Gravidez: Nova: 💷 C		OPTY O TA	utry .			
	Lactante:	OSin O N	lo .			
1		LABORATÓ	810			
	Data de Processamento do CD4 (d-m-a) CD4 (/mm) / CD4 (%)	16	1			
	Carga Viral (CV)					
	G. Brancos (GB)					
5	Neutrofilos (N) (I/mm3 e %)	X				
	Linfócitos (L) (l/mm3 e %)	X				
	Hemoglobina (HgB) (g/dl) Provas hepáticas - ALT / AST (U/L)	VI				
	Glicémia (GL) (g/dl)					
Ureia (	UR) (mg/di) / Creatinina (CR) (mmoi/L)	<u> </u>				
	Amiase					
	Teste de gravidez	O Positivo O Negativo				
	Plaquetas RPR	O Positivo G	Manation			
	ESTADIO ONS	Ültimo Estadio	0			
	Latitude one		•			
	Outros diagnósticos		Anemia Malnutrição Les bre Sarcoma de Kaposi	Diarreia - Falència Terapeutica		
				1		
		fecções Oport				
	e ITS(Tem sintomas sugestivas de ITS)? de TB(Tem sintomas sugestivas de TB)?	a statistic state of a local state of the				
	a Investigação para TB de BK e/ou RX?		Marine and a second			
Data Inicio:	Tratamento de TB (Veja Cartão de TB)	O Sin O N				
LAGA INCO:	Data Fim: Profilaxia com Cotrimoxazol - TPC:					
Data Inicio:	Data Firm:	O Sim O Nã	•			
Data bricier	Profilaxia com 3124 - 1751 Data Fim:	O Sim O Ni	ia .			
Acor	nselhado para Adesão aos Cuidados:	O Sim O N	ia			
		TARV:				
0	lata de Elegibilidade para iniciar o TARVI	-				
Contra	Data de Inicio de TARV: lo de Elepibilidade para obricio do TARV:		[15/dez/2018]			
Crow	Data de Reinicio de TARV:					
		Esquema ARV	1	•		
		Tipoc				
	Hédicamentos ARVs	Telesconteness :				
	Médicamentos ARVs	Interrompeu : Hudança de r	egimet			
	Médicamentos ARVs	Interrompeu :	egimei	•		
	Médicamentos ARVs Outros Medicamentos	Enterrompeu ; Mudança de n	egimet			
		Enterrompeu ; Mudança de n	epimei			
		Interningeu Mudança de n		:		
	Outros Medicamentos	Anemia - /	Neutropenia - N C Panor	:		
		Interninges ( Mudanpa de n Anemia - / Megatotox MP	N Diseutropenia - N D Panor oldade - H U Alterações Paico M D Alergias Cutáneas - AC	• eatile - P ológicas - AP O Neuropatia Perifério O Lipodetrofia - L		
	Outros Hedicamentos Efeitos Secundarios do Tratamento	Anemia - J Mudança de n Anemia - J Mepatotox Ap	V Diseutropenia - N D Panor cidade - H D Alternoles Photo H D Alergias Cutáness - AC cida - Act. D Diarreis - D D I	• eatile - P ológicas - AP O Neuropatia Perifério O Lipodetrofia - L		
	Outros Hedicamentos Efeitas Secundarios do Tratamenta Aderente ao TARY:	Anemia - / Mudança de n Anemia - / Mepatoto: AP Acidose Lá	V Diseutropenia - N D Panor cidade - H D Alternoles Photo H D Alergias Cutáness - AC cida - Act. D Diarreis - D D I	• eatile - P ológicas - AP O Neuropatia Perifério O Lipodetrofia - L		
	Outros Medicamentos Effeitos Secundarios do Tratamento Aderente ao TaRin Data de proxima consulta	Anemia - / Mudança de n Anemia - / Mepatoto: AP Acidose Lá	V Diseutropenia - N D Panor cidade - H D Alternoles Photo H D Alergias Cutáness - AC cida - Act. D Diarreis - D D I	• eatile - P ológicas - AP O Neuropatia Perifério O Lipodetrofia - L		
	Outros Hedicamentos Efeitas Secundarios do Tratamenta Aderente ao TARY:	Anemia - / Mudança de n Anemia - / Mepatotoc MP Mopata - Acidose Lá	V Diseutropenia - N D Panor cidade - H D Alternoles Photo H D Alergias Cutáness - AC cida - Act. D Diarreis - D D I	• eatile - P ológicas - AP O Neuropatia Perifério O Lipodetrofia - L		
	Outros Hedicamentos Effeitos Secundarios do Tratamento Aderente ao TARVI Data de proximo controlo de CD4: Data de proximo controlo de CD4:	Anemia - / Mudança de n Anemia - / Mepatotoc MP Mopata - Acidose Lá	<ul> <li>Meutropenia - N I Panor oldade - H I Altangões Paico</li> <li>Alengias Cutáneos - AC doca - ACL II Diameia - D I I</li> <li>Io</li> </ul>	• eatile - P ológicas - AP O Neuropatia Perifério O Lipodetrofia - L		

	e   Dicionário   Cohort Builder   Repo	orting Administ	
Maria Carlos   ADULTO: SE	GUIMENTO (S.TARV: ADULTO SEGUIMENTO	D)   (Unsaved Form	
FICHA DE SEGUIMENTO PARA ADULTOS			
REPÚBLICA DE MOÇAMBIQUE SERVIÇO NACIONAL DE SAUDE	Nome:Maria Carlos		
Hod. SES - H-10	Data de nascimento: 17/out/2018 Idad	de: 0- Sexo: F	
NID: 01080805/17/00010		a da Pág do pré-TARV)	
Nº do livro TARU: Deta da Consulta	Página do livro TARV: Linho	a da Pág do TARV:	
	Local Desconhecido		
Médice	Enter		
Alturaci (cm)(Útima Alturac )			
Peso(kg) Indice de Masse Corporal (IMC):(kg/m2)			
Classificação Nutricionali			
Apoio Nutricional (ANUT)		rida Datas	
Temperatura (*C):			
Tensilo Arterial (TA)	N I		
Gravidez: Nova: C DUM DPP:	OPTV O TARY		
Lactarte:	OSim O Nilo		
	LABORATÓRIO		
Data de Processamento do CD4 (d-m-a)			
CD4 (/mm) / CD4 (%) Carga Viral (CV)			
G. Brancos (GB)			
Neutrafilos (N) (I/mm3 e %)			
Linfócitos (L) (l/mm3 e %)	N I		
Hemoglobina (HgB) (g/d)			
Proves hepétices - ALT / AST (U/L)			
Glicémia (GL) (g/d)			
Uneia (UR) (mg/d) / Creatinina (CR) (mmol/L) Amilase			
Teste de gravidez	O Positivo O Negativo		
Plaquetas			
RPR.	O Positivo O Negativo		
ESTADIO ONS	Último Estadio 🛛		
	Malária - Anemia - Malnutrição - Leucemia - Ence	whitesatio	
Outros diagnósticos	Otte Febre Sarcoma de Kaposi Diameia O Fa		
	lecções Oportunistas		
Rastreio de ITS(Tem sintomas sugestivas de ITS)? Rastreio de TB(Tem sintomas sugestivas de TB)?	O Sim O Não O Sim O Não		
Resultado para a Investigação para 18 de BK e/ou RX?	O Positivo - O Negativo		
Tratamento de TB (Veja Cartão de TB)			
Deta Inicio: Deta Fim:	OSm O Nio		
Profilacia com Cotrimosazol - TPC: Data Inicio: Data Fim:	O Sim O Não		
Profilaxia com Dan - 195) Data Snicior Data Fimi	OSim Otalo		
Aconselhado para Adesão aos Cuidados:	Osim Onlis		
	TARV:		
Data de Elegibilidade para iniciar o TARVI			
Data de Inicio de TARVI	[15/dez/2018]		
Critério de Elephilidade para cónicio do TARVI	•		
Data de Reinicio de TARV:			
1000 Contraction (1997)	Esquema ARVI		
Hédicamentos ARVs	Interrompeu pori		
	Hudança de regimei 🔹	•	
Outros Medicamentos		•	
	Anemia - A O Neutropenia - N O Pancreatite - P		
	Unepatotoxicidade - H U Alterações Psicológicas - AP U NP	Neuropatia Periférica -	
Efeitos Secundarios do Tratamento	Mopatia - H O Alergias Cutáneas - AC O Upodistrofia	8 - L	
Efeitos Secundarios do Tratamento			
	Acidose Láctica - AcL Diameia - D Outros:		
Aderente ao TARVI			
	Acidose Láctica - AcL Diameia - D Outros:		
Aderente ao TARV: Data da proxima consulta	Acidose Láctica - AcL Diameia - D Outros:		
Ademente ao TARVI Data da proxima consulta Data do proximo controlo de CD4:	Addee Láctos - Ad, U Diarreis - D U Outros:		

Annex 3- OpenMRS EPTS Pediatria Seguimento

int	Mari		-	TO (S.TARV: PEDIATRIA SEGU	ILMENTO)   (Unsaved F	
		FICHA DE SEGUIMENTO PARA				
	SERVIÇO NACI	REPÚBLICA DE MOÇAMBIQUE SERVIÇO NACIONAL DE SAÚDE		Nome:Maria Carlos		
	Hod. S	LS - H-10		acimento: 17/out/2018	Sexo: F	
	NSD: 01080805/17/00010	Nº do livro pré-TARVI Nº do livro TARVI	Página do Página do	ivro pre-TARV:	Linha da Pág do pré-TARVI Linha da Pág do TARVI	
	PCR-DNA - 1º Resultado:	POS O NEG O IND Deter	and the second se	CR-DNA - 2ª Resultado: O POS O NEG	and the second se	
		Resultado de teste Rápido de				
		Deta da Consulta				
		Unidade Sanitária Médico	Local De	conhecido •		
		Idade anos / meses	0/0			
		Peso (kg)				
		Estatura (cm)				
	Peso/Estatura	(DP) ou INC (kp/m2) pera idade				
	Contempotentian (In/ Inc	Classificação Nutricional: famento Nutricional (ATRUCSR)	(Car star	Tipe: CSB Pumpy Nut Pape Er	and a state of the	
		-Motor Adequado para a idade?			inquecios - outro	
		Temperatura (ºC):				
	1		LABORA	róitto		
	Duta de	Processamento do CD4 (d-m-a)				
		CD4 (/mm) / CD4 (%) Carga Viral (CV)	-			
		G. Brancos (GB)				
		Neutrofilos (N) (Vmm3 e %)				
		Linfócitos (L) (Vimm3 e %)	1			
		Hemoglobina (HgB) (g/d)				
	Pri	oves hepétices - ALT / AST (U/L)	1			
	Unaia (192) (m.	Glicémia (GL) (g/dl) g/dl) / Creatinina (CR) (mmol/L)				
		Amiase				
		Plaquetas				
		ESTADIO OHS	Último Est	edio []		
		Outros diagnósticos		Anemia - Halnutrição - Leucemia Febre - Sarcoma de Kaposi - Diarrei	😳 Encefalopatia a 🖾 Paléncia Terapeutica	
		1.	lecoles De	ortunistas		
	Rastreio de TB(T	em sintomas sugestivas de TB)?	which the rest of the local division of the			
		Resultado do BK (POS/NEG)	O POS O	NEG		
	Data Inicio:	ento de TB (Veja Cartão de TB): Deta Fim:	OSON			
	Pri	ofilaxia com Cotrimoxazol - TPC:	OSON	8		
	Deta Inicier	Profilaxia com 3104 - TPD:				
	Data Inicior	Deta Fim:	OSON			
	Recebeu educaçã	o para Adesão aos Cuidados:	OSON			
		Sepibilidade para iniciar o TARV:	TAR			
	Cata de l	Depbildade para iniciar o TARV: Data de Inicio de TARV:	-	[15/dez/2018]		
		Deta de Reinicio de TARV:				
			Esquerna J		•	
		Médicamentos ARVs	Tipo: Snterromp	N port	•	
				e regime:	•	
			-		•	
		Outros Medicamentos				
			-		•	
			Anemia	· A ONeutropenia · N OPencreatite ·	P	
	EN	eitos Secundarios do Tratamento	NP	toxicidade - H 🛄 Alterações Psicológicas		
				Mopatia - M C Alergias Cutâneas - AC C Lipodistrofia - L Acidose Láctica - Aci, C Diameia - D C Outros:		
		Aderente ao TARV:				
		Deta da proxima consulta	the state of the local division of the local			
		sta do proximo controlo de CD4:				
		eferido para outro sector clinico:	_	•		
	B-4-	rido para serviços comunitários:				
	Kete	Observacies:	_			